NOVEL CRYSTALS OF HYDROXAMIC ACID DERIVATIVE, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION

1 . A crystal of a hydrate of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 3.8±0.2°, 7.7±0.2°, 10.8±0.2°, 12.0±0.2°, and 14.4±0.2° in powder X-ray diffraction.

2 . A crystal of a hydrate of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 3.8±0.2°, 7.7±0.2°, 10.8±0.2°, 12.0±0.2°, 14.4±0.2°, 16.3±0.2°, 17.0±0.2°, and 21.8±0.2° in powder X-ray diffraction.

3 . A crystal of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 8.2±0.2°, 12.4±0.2°, 13.3±0.2°, 15.2±0.2°, and 16.2±0.2° in powder X-ray diffraction.

4 . A crystal of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 8.2±0.2°, 12.4±0.2°, 13.3±0.2°, 15.2±0.2°, 16.2±0.2°, 19.0±0.2°, 20.2±0.2°, and 22.8±0.2° in powder X-ray diffraction.

5 . A pharmaceutical composition which comprises the crystal according to claim 1 .

6 . A method for producing the crystal according to claim 1 , comprising stirring a mixture containing (1) (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide, (2) water, and (3) an organic solvent, wherein the organic solvent is one or two or more selected from alcohols, ethers, ketones, and nitriles.

7 . The production method according to claim 6 , wherein the alcohols are methanol, ethanol and 2-propanol, the ether is tetrahydrofuran, the ketone is acetone, and the nitrile is acetonitrile.

8 . The production method according to claim 6 , wherein (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide is a crystal of a hydrate of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 3.5±0.2°, 16.2±0.2°, 16.5±0.2°, 22.4±0.2°, and 22.7±0.2° in powder X-ray diffraction.

9 . A method for producing the crystal according to claim 3 , comprising stirring a mixture containing (1) (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide and (2) an organic solvent, in the absence of water, wherein the organic solvent is one or two or more selected from aliphatic hydrocarbons, alcohols, ethers, ketones, esters, sulfoxides, nitriles, and amides.

10 . The production method according to claim 9 , wherein the aliphatic hydrocarbon is heptane, the alcohols are methanol, ethanol and 2-propanol, the ether is tetrahydrofuran, the ketone is acetone, the ester is ethyl acetate, the sulfoxide is dimethyl sulfoxide, the nitrile is acetonitrile, and the amide is dimethylacetamide.

11 . The production method according to claim 9 , wherein (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide is a crystal of a hydrate of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 3.8±0.2°, 7.7±0.2°, 10.8±0.2°, 12.0±0.2°, and 14.4±0.2° in powder X-ray diffraction.

12 . A pharmaceutical composition which comprises the crystal according to claim 2 .

13 . A pharmaceutical composition which comprises the crystal according to claim 3 .

14 . A pharmaceutical composition which comprises the crystal according to claim 4 .

15 . A method for producing the crystal according to claim 2 , comprising stirring a mixture containing (1) (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide, (2) water, and (3) an organic solvent, wherein the organic solvent is one or two or more selected from alcohols, ethers, ketones, and nitriles.

16 . The production method according to claim 15 , wherein the alcohols are methanol, ethanol and 2-propanol, the ether is tetrahydrofuran, the ketone is acetone, and the nitrile is acetonitrile.

17 . The production method according to claim 15 , wherein (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide is a crystal of a hydrate of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 3.5±0.2°, 16.2±0.2°, 16.5±0.2°, 22.4±0.2°, and 22.7±0.2° in powder X-ray diffraction.

18 . A method for producing the crystal according to claim 4 , comprising stirring a mixture containing (1) (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide and (2) an organic solvent, in the absence of water, wherein the organic solvent is one or two or more selected from aliphatic hydrocarbons, alcohols, ethers, ketones, esters, sulfoxides, nitriles, and amides.

19 . The production method according to claim 18 , wherein the aliphatic hydrocarbon is heptane, the alcohols are methanol, ethanol and 2-propanol, the ether is tetrahydrofuran, the ketone is acetone, the ester is ethyl acetate, the sulfoxide is dimethyl sulfoxide, the nitrile is acetonitrile, and the amide is dimethylacetamide.

20 . The production method according to claim 18 , wherein (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N′,2-dimethylmalonamide is the crystal according to claim 1 .